Kexing Biopharm Advances GB10 Into Phase I Trial For Neovascular AMD In China
First patient dosed in Phase I study of high concentration bispecific antibody candidate targeting VEGF and Ang 2, with the potential to extend ...
BioPharma APAC 2
Covers: China & GeopoliticsHealthcare
Scientific Infrastructure or Expensive Theatre? AI Discovery's Reckoning in Asia
U.S. export controls on advanced AI chips mean Chinese and some other ... Advances its own therapeutic programs and carries the risk. Sells ...